Page 47 - Neuropsychiatric.indd

14. นฤมล เจริญศิริพรกุล. การแพ้ยา อาการไม่พึงประสงค์จากยาที่เกิดต่อผิวหนังและตับ. 2561
15. Tisdale JE, Miller DA. Drug-Induced Diseases: Prevention, Detection, and Management.

United States: American Society of Health-System Pharmacists, Inc., 2018.
16. Dipiro JT, Yee GC, Posey LM, Haines ST, Nolin TD, Ellingrod V. Pharmacotherapy: A
pathophysiologic approach. 11th ed. United States: McGraw Hill Companies, Inc, 2020.
17. Choudhury A, Sahu T, Ramanujam PL, Banerjee AK, Chakraborty I, Kumar K, et al.

Neurochemicals, behaviours and psychiatric perspectives of neurological diseases.
Neuropsychiatry (London). 2018;8(1):395-424.
18. Sheffler ZM, Reddy V, Pillarisetty LS. Physiology, Neurotransmitters. [accessed 10 May

2021]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539894/#_article-
25841_s4_.
19. Seethalakshmi D. Neurotransmitters and their impact on mental illness. IJSR.
2017;6(5):1512-8.
20. Pickar D, Litman RE, Konicki PE, Wolkowitz OM, Breier A. Neurochemical and neural

mechanisms of positive and negative symptoms in schizophrenia. Mod Probl
Pharmacopsychiatry. 1990;24:124-51.
21. Cowen PJ. Neuroendocrine and neurochemical process in depression. Psychopathology

Review. 2016;3(1):3-15.
22. Kaur S, Singh R. Role of different neurotransmitters in anxiety: a systematic review. Int J
Pharm Sci Res. 2017;8(2):411-21.
23. Sarter M, Bruno J, Parikh V. Abnormal neurotransmitter release underlying behavioral and

cognitive disorders: toward concepts of dynamic and function-specific ys
regulation. Neuropsychopharmacol. 2007;32:1452–61.
24. Akyuz E, Polat AK, Eroglu E, Kullu I, Angelopoulou E, Paudel YN. Revisiting the role of
neurotransmitters in epilepsy: An updated review. Life Sci. 2021;265:118826.

25. Doummar D, Moussa F, Nougues MC, Ravelli C, Louha M, Whalen S, et al. Monoamine
neurotransmitters and movement disorders in children and adults. Rev Neurol (Paris).
2018;174(9):581-8.
26. Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central

nervous system-mediated effects. Ochsner J. 2013;13(2):214-23.
27. Fasipe OJ. Neuropharmacological classification of antidepressant agents based on their
mechanisms of action. Arch Med Health Sci 2018;6:81-94.
28. Sub Laban T, Saadabadi A. Monoamine oxidase inhibitors (MAOI). [accessed 10 May 2021].

Available from: https://www.ncbi.nlm.nih.gov/books/NBK539848/
29. Chu A, Wadhwa R. Selective serotonin reuptake inhibitors. [accessed 11 May 2021].
Available from: https://www.ncbi.nlm.nih.gov/books/NBK554406/
30. Moraczewski J, Aedma KK. Tricyclic antidepressants. [accessed 11 May 2021]. Available

from: https://www.ncbi.nlm.nih.gov/books/NBK557791/

26
26